<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743053</url>
  </required_header>
  <id_info>
    <org_study_id>CTP003</org_study_id>
    <nct_id>NCT01743053</nct_id>
  </id_info>
  <brief_title>A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avita Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NAMSA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avita Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomised, open label, controlled pilot study to evaluate the safety&#xD;
      and preliminary effectiveness of the ReCell Autologous Cell Harvesting Device (ReCell) for&#xD;
      the management of chronic leg ulcers associated with venous insufficiency. Outcome will be&#xD;
      compared between study participants receiving standard care (debridement, compression&#xD;
      therapy) and participants receiving ReCell in addition to standard care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound healing</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary objective of the study is to assess the difference in incidence of ulcer closure (investigator assessed as complete epithelialisation without drainage) between the ReCell group and the control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wounds characterization/Quality of Life</measure>
    <time_frame>At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks)</time_frame>
    <description>Wound area&#xD;
Wound volume&#xD;
Pain&#xD;
Recurrence&#xD;
Health-related Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dressing Change</measure>
    <time_frame>At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks) until healed</time_frame>
    <description>- Dressing change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Venous Leg Ulcers</condition>
  <arm_group>
    <arm_group_label>Control: Standard Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReCell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Care plus ReCell</intervention_name>
    <arm_group_label>ReCell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <arm_group_label>Control: Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic venous leg ulcer (CEAP Clinical classification of 6)&#xD;
&#xD;
               1. Confirmed, actively managed venous reflux&#xD;
&#xD;
               2. No exposed tendon or bone&#xD;
&#xD;
               3. Ulcer is &gt;4 weeks in duration&#xD;
&#xD;
               4. Ulcer surface area between 2cm2 and 80cm2&#xD;
&#xD;
          2. ABI ≥ 0.8&#xD;
&#xD;
          3. The patient is 18 years of age or older&#xD;
&#xD;
          4. The patient is willing to complete all follow-up evaluations required by the study&#xD;
             protocol&#xD;
&#xD;
          5. The patient is able to abstain from any other treatment of the ulcer for the duration&#xD;
             of the study, unless medically necessary&#xD;
&#xD;
          6. The patient agrees to abstain from enrolment in any other clinical trial for the&#xD;
             duration of the study&#xD;
&#xD;
          7. The patient is able to read and understand instructions and give voluntary written&#xD;
             informed consent&#xD;
&#xD;
          8. The patient is able and willing to follow the protocol requirements (including&#xD;
             compression therapy)&#xD;
&#xD;
          9. Patients enrolling at any site in France must have an affiliation to a social security&#xD;
             scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Study treatment area has exposed bone or tendon&#xD;
&#xD;
          2. Poorly controlled diabetes&#xD;
&#xD;
          3. Arterial insufficiency (ABI &lt; 0.8)&#xD;
&#xD;
          4. Pregnant/lactating females (self-reported or tested, per institutional requirements)&#xD;
&#xD;
          5. The patient has an active wound infection requiring antibiotic therapy&#xD;
&#xD;
          6. The patient has had a prior surgical treatment of the ulcer within the past 60 days&#xD;
&#xD;
          7. The patient has a life expectancy of 1-year or less&#xD;
&#xD;
          8. The patient has a severe dermatological disorder (e.g. severe psoriasis, epidermolysis&#xD;
             bullosa, pyoderma gangrenosum).&#xD;
&#xD;
          9. The patient is unable to follow the protocol&#xD;
&#xD;
         10. The patient is taking, or has taken in the past 60 days, mycophenolate mofetil or&#xD;
             &gt;10mg of corticosteroids per day.&#xD;
&#xD;
         11. The patient has other concurrent conditions that in the opinion of the investigator&#xD;
             may compromise patient safety or study objectives&#xD;
&#xD;
         12. The patient has a known hypersensitivity to trypsin or Compound Sodium Lactate for&#xD;
             Irrigation (Hartmann's) solution.&#xD;
&#xD;
         13. The patient is a vulnerable or protected adult.&#xD;
&#xD;
         14. The patient is unable to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals - Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF24 0DE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doncaster and Bassetlaw Hospitals</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hospitals - James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester - Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

